Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5282043
Max Phase: Preclinical
Molecular Formula: C18H14ClNO3S
Molecular Weight: 359.83
Associated Items:
ID: ALA5282043
Max Phase: Preclinical
Molecular Formula: C18H14ClNO3S
Molecular Weight: 359.83
Associated Items:
Canonical SMILES: COc1cc(Cl)cc(/C=C2\SC(c3ccc(C)cc3)=NC2=O)c1O
Standard InChI: InChI=1S/C18H14ClNO3S/c1-10-3-5-11(6-4-10)18-20-17(22)15(24-18)8-12-7-13(19)9-14(23-2)16(12)21/h3-9,21H,1-2H3/b15-8-
Standard InChI Key: FUEVYCYBGSCYIY-NVNXTCNLSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 359.83 | Molecular Weight (Monoisotopic): 359.0383 | AlogP: 4.42 | #Rotatable Bonds: 3 |
Polar Surface Area: 58.89 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 8.69 | CX Basic pKa: | CX LogP: 4.25 | CX LogD: 4.23 |
Aromatic Rings: 2 | Heavy Atoms: 24 | QED Weighted: 0.82 | Np Likeness Score: -1.06 |
1. Fu S, Zheng Q, Zhang D, Lin C, Ouyang L, Zhang J, Chen L.. (2022) Medicinal chemistry strategies targeting PRMT5 for cancer therapy., 244 [PMID:36274274] [10.1016/j.ejmech.2022.114842] |
Source(1):